Becton Dickinson and Company (BDX)
Health Care2 articles
Price chart
Becton Dickinson and Company (BDX) overview
Becton Dickinson is a major maker of medical supplies and devices. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Becton Dickinson and Company trades on the NYSE under the ticker symbol BDX. As of the most recent market data, the stock was priced around $158.17, down 1.10% on the session.
Over the past 52 weeks, BDX has traded between $127.59 and $187.35. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 27.9, a common gauge of how richly the market prices the company's earnings. Becton Dickinson and Company also pays a dividend, currently yielding around 2.63%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch BDX
As one of the larger companies in the Health Care sector, Becton Dickinson and Company is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch BDX for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest BDX news
Becton Dickinson (BDX) Stock Sees 6% Rise After Earnings Beat
Becton, Dickinson and Company (NYSE: BDX) experienced a nearly 6% increase in stock price following a strong earnings report on May 7. The company raised its full-year earnings forecast, highlighting excellent execution across its medical supply and technology divisions. Jim Cramer noted this was the lowest valuation level he has seen for the stock, suggesting potential further upside. Despite near-term challenges from increased AI spending, BDX's positive earnings reflect strong operational performance and market positioning.
Read More: Becton Dickinson (BDX) Stock Sees 6% Rise After Earnings Beat
Becton Dickinson (BDX) Price Target Trimmed to $159 by Piper Sandler
Piper Sandler has reduced the price target for Becton, Dickinson and Company (BDX) from $170 to $159 while maintaining a Neutral rating. This adjustment was made on April 17, 2026, to align with management's revenue growth guidance. Additionally, RBC Capital Markets lowered its price target for BDX to $175 from $195, citing stable fundamentals in the MedTech sector. Both firms note that current sentiment around BDX may create investment opportunities, but they expect the stock to remain range-bound due to a lack of clear catalysts.
Read More: Becton Dickinson (BDX) Price Target Trimmed to $159 by Piper SandlerMore Health Care stocks
Frequently asked questions
Is Becton Dickinson and Company in the S&P 500?
Yes. Becton Dickinson and Company (BDX) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is BDX in?
Becton Dickinson and Company is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest BDX news?
This page collects recent Becton Dickinson and Company (BDX) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Becton Dickinson and Company's stock price?
As of the most recent market data, Becton Dickinson and Company (BDX) traded at approximately $158.17. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is BDX's P/E ratio?
BDX trades at a trailing price-to-earnings ratio of about 27.9. The P/E ratio compares a company's share price to its earnings per share.